![Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation](https://gastriccancer.org/wp-content/uploads/2018/11/680522_IMG_173101_HR.jpg)
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
![Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/38/4/2419/F1.large.jpg)
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research
![Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS‐ 102) | Semantic Scholar Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS‐ 102) | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1574e38909cc231b8f7b371096b24e3640983a36/3-Table1-1.png)
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS‐ 102) | Semantic Scholar
![Mode of action of TAS-102. α,α,α-Trifluorothymidine (FTD) is converted... | Download Scientific Diagram Mode of action of TAS-102. α,α,α-Trifluorothymidine (FTD) is converted... | Download Scientific Diagram](https://www.researchgate.net/publication/256470080/figure/fig5/AS:202889797607434@1425384105739/Mode-of-action-of-TAS-102-a-a-a-Trifluorothymidine-FTD-is-converted-by-TK-to-its.png)
Mode of action of TAS-102. α,α,α-Trifluorothymidine (FTD) is converted... | Download Scientific Diagram
![LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy](https://www.lonsurfhcp.com/Content/img/mCRC/lonsurf-mcrc-reduced-mortality-risk-mobile.png)
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
![TAS-102 (Trifluridine-tipiracil hydrochloride mixture) | Nucleoside Antimetabolite/Analog Inhibitor | Cas# 733030-01-8 - GlpBio TAS-102 (Trifluridine-tipiracil hydrochloride mixture) | Nucleoside Antimetabolite/Analog Inhibitor | Cas# 733030-01-8 - GlpBio](https://www.glpbio.com/media/struct/GC1/GC19348.png)
TAS-102 (Trifluridine-tipiracil hydrochloride mixture) | Nucleoside Antimetabolite/Analog Inhibitor | Cas# 733030-01-8 - GlpBio
![TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/cc4083cd-2659-41e7-9bce-cf5c88cf963f/gr1_lrg.gif)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology
![JCM | Free Full-Text | Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study JCM | Free Full-Text | Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study](https://www.mdpi.com/jcm/jcm-12-00596/article_deploy/html/images/jcm-12-00596-g001.png)
JCM | Free Full-Text | Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study
![SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer | CCO SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer | CCO](https://d8tzmbmuvomgp.cloudfront.net/medialibrary/00008/31A92BDB-C028-4590-9ADA-2A478B1A9313.png)
SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer | CCO
![Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer | Anticancer Research Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/41/4/2157/F1.large.jpg?width=800&height=600&carousel=1)
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer | Anticancer Research
![TAS-102 | Trifluridine | Tipiracil | CAS#733030-01-8 | CAS#183204-74-2 | CAS#70-00-8 | Thymidine Phhosphorylase Inhibitor | Cytotoxic Pyrimidine Analog | MedKoo TAS-102 | Trifluridine | Tipiracil | CAS#733030-01-8 | CAS#183204-74-2 | CAS#70-00-8 | Thymidine Phhosphorylase Inhibitor | Cytotoxic Pyrimidine Analog | MedKoo](https://www.medkoo.com/uploads/product/TAS-102__Trifluridine_Tipiracil_HCl_/image/TAS-102.gif)